BC Innovations | Sep 4, 2008
Cover Story

CB1's Peripheral Vision

In 2007 an FDA panel recommended against approval of sanofi-aventis Group 's Accomplia rimonabant for obesity. Neurological safety concerns arose due to increased levels of seizures and suicidality in patients taking the cannabinoid CB 1...
BC Innovations | Sep 4, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Cannabinoid CB1 receptor A study in mice and human tissue suggests that CB1 receptor agonists could be useful...
BC Week In Review | Aug 11, 2008
Company News

Meda, Valeant Pharmaceuticals International deal

Meda will acquire Valeant’s Eastern and Western European business operations for $392 million in cash. Meda said the deal gives it a foothold in Russia, where it plans to introduce its own products, as well...
BC Extra | Aug 5, 2008
Company News

Meda acquiring Valeant units in Europe

Valeant (NYSE:VRX) will sell its operations in Western and Eastern Europe, including Russia, to Meda (SSE:MEDA) for $392 million in cash. Meda said the deal gives it a foothold in Russia, where it plans to...
BioCentury | Jun 18, 2007
Regulation

Zimulti's central concerns

Although sanofi-aventis Group 's Zimulti rimonabant is approved in 37 countries to treat obesity, both FDA and its Endocrinologic and Metabolic Drugs Advisory Committee indicated last week that they are not comfortable approving a compound...
BC Week In Review | Feb 26, 2007
Clinical News

Cesamet nabilone: IND submitted

VRX plans to begin a U.S. Phase III trial in an undisclosed number of patients. Cesament is approved to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately...
BC Week In Review | Feb 26, 2007
Company News

Cambridge Laboratories, Valeant Pharmaceuticals International sales and marketing update

Cambridge Laboratories granted VRX rights to commercialize nabilone in the U.K. and the EU to treat chemotherapy-induced nausea and vomiting (CINV). Cambridge will receive $14 million up front. Nabilone is marketed in the U.K. and...
BC Week In Review | Feb 19, 2007
Company News

Cambridge Laboratories, Valeant sales and marketing update

VRX acquired rights to market Cambridge Laboratories' nabilone in the U.K. and other undisclosed European countries to treat chemotherapy-induced nausea and vomiting (CINV). VRX markets the cannabinoid agonist as Cesamet in the U.S. and Canada....
BC Week In Review | Nov 6, 2006
Company News

Par Pharmaceutical, Valeant sales and marketing update

VRX ended an October 2005 deal for PRX to promote VRX's Cesamet nabilone oral capsules in the U.S. (see BioCentury, Nov. 7, 2005). The cannabinoid agonist is approved to treat nausea and vomiting associated with...
BC Week In Review | Aug 21, 2006
Company News

Valeant, Par Pharmaceuticals Companies Inc. sales and marketing update

The partners launched Cesamet nabilone oral capsules in the U.S. The cannabinoind agonist is used to treat nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetics....
Items per page:
1 - 10 of 14